Class Action Filed Against ESSA Pharma Inc. (EPIX) Seeking Recovery For Investors – Contact The Gross Law Firm
Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
Shareholders that lost money on Elastic N.V. (ESTC) should contact Levi & Korsinsky about pending Class Action - ESTC
NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Elastic N.V. (NYSE:ESTC) investment and want to learn about a potential recovery under the federal securities laws,
HealthDay on MSN16h
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate CancerFor patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Medpage Today on MSN6d
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPCShe noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...
Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...
If you purchased or acquired securities in ESSA Pharma between December 12, 2023 and October 31, 2024 and would like to ...
Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...
For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback